Calidi Biotherapeutics (CLDI) Accumulated Expenses (2021 - 2025)

Calidi Biotherapeutics has reported Accumulated Expenses for 5 years, with the latest figure at $100000.0 in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Expenses fell 79.17% year-over-year to $100000.0; the trailing twelve-month figure through Dec 2025 stood at $100000.0 (down 79.17% YoY), and the FY2025 full-year result was $100000.0, down 79.17% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $100000.0, down from $778000.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $5.1 million in Q4 2022, with the low at $19000.0 in Q3 2023.
• Average Accumulated Expenses over 5 years is $1.2 million, with a median of $400000.0 recorded in 2024.
• Year-over-year, Accumulated Expenses soared 2005.26% in 2024 and slumped 99.21% in 2025.
• Tracing CLDI's Accumulated Expenses over 5 years: stood at $347146.0 in 2021, then soared by 1381.22% to $5.1 million in 2022, then tumbled by 89.58% to $536000.0 in 2023, then decreased by 10.45% to $480000.0 in 2024, then tumbled by 79.17% to $100000.0 in 2025.
• The last three Accumulated Expenses figures came in at $100000.0 (Q4 2025), $778000.0 (Q3 2025), and $441000.0 (Q2 2025), per Business Quant data.

Peer Comparison